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ABSTRACT
Objective: The present aim is to develop simple, precise, and accurate reverse phase high performance liquid chromatographic method (RP-HPLC) for 
the simultaneous assay of artemether and lumefantrine in fixed combined dosage form.
Methods: The chromatographic study was carried out on Hypersil C18 column (250×4.6 mm, 5 μ) with mobile phase containing a mixture of KH2PO4 
buffer (pH-3.5) and acetonitrile in the ratio of 45:55% v/v at a flow rate of 1.0 ml/minute with ultraviolet detection at 218 nm in ambient column 
temperature.
Results: Using the optimized chromatographic conditions artemether and lumefantrine eluted with retention times of 2.207 and 3.733 minutes, 
respectively. The method was validated according to ICH guidelines with good reproducibility and linear responses, y=60.813.x+629.53 (r²=0.9982) 
for artemether and y=88.3108.x+2370.2 (r²=0.9912). The % relative standard deviations of intra-day precision was ranged 0.378% and 1.26% for 
artemether and 0.459% and 1.15% for lumefantrine, respectively. The percentage recoveries were ranged from 99.96% to 100.02% for artemether 
and 99.96-99.97% for lumefantrine, respectively.
Conclusions: The developed RP-HPLC method was validated as per ICH guidelines and was found to be best suitable for pharmacokinetic studies of 
these mentioned drugs.
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INTRODUCTION
Artemether, (Fig. 1), (3R,5aS,-6R, 8aS,9R,10S,12R,12aR)-decahydro-
10-methoxy-3,6,9- trimethyl- 3,12-epoxy-12H-pyrano [4,3-j]-1,2-
benzodioxepine is an antimalarial agent used to treat acute uncomplicated 
malaria [1,2]. The mechanism of action involves interaction of the 
peroxide-containing drug with heme, thereby resulting in the formation 
of a range of potentially toxic oxygen and carbon-centered radicals.
Azithromycin (Fig. 2), 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-
chlorophenyl) methylidene]-9H-fluoren-4-yl]ethan-1-ol [3,4] is an 
antimalarial agent used to treat acute uncomplicated malaria [3]. The 
exact mechanism by which lumefantrine exerts its antimalarial effect 
is unknown. It was assumed that lumefantrine inhibits the formation 
of β-hematin by forming a complex, thereby inhibiting nucleic acid and 
protein synthesis.
Combination of these two drugs is available in the local pharmacy in 
the brand name of combither oral tablets (artemether 20 mg and 
lumefantrine 120 mg) used in the treatment of acute uncomplicated 
malaria caused by plasmodium falciparum [1,5].
Very few high performance liquid chromatographic (HPLC) methods 
were reported for the determination of artemether and lumefantrine 
in combination forms [6-11]. Basing on this accord, it made essential 
to develop a new reverse phase HPLC method (RP-HPLC) for routine 
analysis of the above said drugs in combined formulations, and in this 
accord, attempts were made by the author to develop simple, precise, 
and accurate RP-HPLC method for the simultaneous assay of the titled 
drugs and extended it for their determination in formulations.
METHODS
Instrumentation
The present chromatographic analysis was carried on water’s 2695 
HPLC system provided with Hamilton Syringe, Hypersil C18 column 
(250×4.6 mm, 5 μ), auto sampler and 2996 photodiode array detector. 
Data were acquired and processed with Empower 2 software. Shimazdu 
electronic weighing balance (Model BL 220 H) was used for weighing 
the standards and samples. Elico pH meter (Hyderabad, India) LI 120 
model was used for pH measurements.
Chemicals and reagents
Pharmaceutically grade pure sample of artemether and lumefantrine 
were obtained from Euphoria Healthcare and Spirochem Life sciences, 
Private Limited Mumbai, as gifted samples and their commercial dosage 
forms in the brand name of combither oral tablets (artemether 20 mg 
and lumefantrine 120 mg) were procured from the local pharmacy. 
Milli-Q water, acetonitrile (HPLC grade), orthophosphoric acid 
(GR grade), and potassium dihydrogen orthophosphate monohydrate 
(GR grade) were obtained from Qualigens Ltd., Mumbai. All dilutions 
were performed in standard Class-A, volumetric glassware.
Mobile phase preparation
Prepare a filtered and degassed mixture of phosphate buffer (pH-3.5) 
and acetonitrile in the ratio of 45:55% v/v, respectively.
Preparation of phosphate buffer
The buffer was prepared by dissolving 2.72 g of potassium dihydrogen 
phosphate in 1000 ml of milli-Q water. The pH of the buffer solution was 
adjusted to 3.5±0.05 with ortho phosphoric acid.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Diluent preparation
Mobile phase is used as diluent in the present assay.
Preparation of stock and working standard solutions
Standard stock solutions of the present studied drugs were prepared 
by weighing accurately 10 mg of artemether and 20 mg of lumefantrine 
were transferred into a clean and dry 100 ml volumetric flask. To this 
flask, about 70 ml of diluent was added and sonicated for 5 minutes. 
Later, the volume of the flask was made up to the mark with the same 
diluent (concentrations 100 µg/ml for artemether and 200 µg/ml, 
for lumefantrine). From the above prepared stock solution pipette 
out and transfer suitable aliquots into a clean dry 10 ml volumetric 
flask, and mixed with the same diluent to obtain final concentrations 
of 10-30 µg/ml for artemether and 20-60 µg/ml, for lumefantrine, 
respectively.
Preparation of sample solution
20 tablets of combither oral tablets (artemether 20 mg and lumefantrine 
120 mg) purchased from the local pharmacy were powdered to 
fine powder. Then, sample solution was prepared by weighing and 
transferring equivalently 100 mg of the fine powder of formulation 
mixture into a 100 ml clean and dry volumetric flask containing 70 ml 
of diluent and sonicated to dissolve it completely and the volume made 
up to the mark with the same solvent. From above prepared stock 
sample solution pipette out suitable aliquots and transferred into a clean 
and different dry 10ml volumetric flasks and diluted to the mark with 
the same diluent (concentration of 10-30 µg/ml for artemether and 
20-60 µg/ml for lumefantrine), respectively. A volume of 20 μl volumes of 




In the development of the present method for the selected drugs a 
number of experimental trials were made by changing the columns 
and mobile phase by varying its composition as well as by changing 
the solvents. These trials had resulted in low resolution with 
asymmetric peaks and also peaks with more tailing factors and long 
elution times.
However, finally, the Hypersil C18 column (250×4.6 mm, 5 μ) with 
mobile phase of KH2PO4 buffer (pH-3.5) and acetonitrile in the ratio of 
45:55% v/v at a flow rate of 1.0 ml/minute and ultraviolet detection 
at a wavelength of 218 nm in ambient column temperature resulted 
in excellent elution of the two drugs with low retention and run times. 
The same buffer was used as diluent in the preparation of standard and 
sample solutions. With the above optimized conditions, the cited drugs 
(artemether and lumefantrine) were resolved with retention times 
(2.207 minutes and 3.733 minutes for artemether and lumefantrine, 
respectively) with theoretical plates and good resolution, respectively 
(Fig. 3).
Fig. 1: Chemical structure of artemether
Fig. 2: Chemical structure of azithromycin
Fig. 3: Chromatogram of artemether and lumefantrine
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Method validation
The developed RP-HPLC method was validated in accordance with ICH 
guidelines [12] using the following parameters.
System suitability
System suitability parameters such as number of theoretical plates, 
HETP and peak tailing were determined for both the drugs with 
the proposed method and their values were tabulated in (Table 1), 
respectively. It was found that all the system suitability parameters 
for developed RP-HPLC method for artemether and lumefantrine were 
within the acceptance criteria.
Specificity
Blank and placebo interference
The specificity of the proposed method was established by injecting 
blank and placebo using the above chromatographic conditions. The 
chromatograms of blank and placebo solution showed no additional 
peaks at the retention time of artemether and lumefantrine peak 
revealing specificity of the developed RP-HPLC method.
Linearity and detector response
The linearity was performed by plotting, and calculating linear 
regression analysis for the standard curves of artemether and 
lumefantrine (Figs. 4 and 5), respectively. Two standard curves were 
obtained in the concentration range of 10-30 µg/ml for artemether and 
20-60 µg/ml for lumefantrine, respectively. The slope and intercept 
value for calibration curve were y=60.813.x+629.53 (r²=0.9982) for 
artemether and y=88.3108.x+2370.2 (r²=0.9912) for lumefantrine, 
respectively. It was revealed that an excellent correlation exists 
between response factor and concentration of cited drugs within the 
concentration range indicated as above respectively (Table 2).
The limit of detection values for artemether and lumefantrine were 
found to be 0.0428 µg/mL and 0.0940 µg/mL, respectively, and the limit 
of quantitation values for artemether and lumefantrine were found 
to be 0.1429 µg/mL and 0.3138 µg/mL, respectively, revealing good 
sensitivity of the proposed method (Table 3).
Precision
The precision of the developed method was evaluated using intra-day 
analysis by injecting six replicate injections of 100% test concentration 
of the above mentioned drugs and the results were expressed in 
terms of standard deviation and % relative standard deviation 
(%RSD), respectively. From the results (%RSD of 0.378 and 1.26% for 
artemether and 0.459 and 1.15% for lumefantrine), it was revealed that 
the developed method was found to be precise, respectively (Table 4).
Accuracy
The accuracy of the proposed method was determined at three 
concentration levels (50,100 and 150%) by recovery experiments 
which were carried out in triplicate preparations as per the proposed 
method. The percentage recoveries ranged from 99.96 to 100.02% 
for artemether and 99.96-99.97% for lumefantrine, respectively, 
revealing that the developed RP-HPLC method was found to be 
accurate (Table 5).
Robustness studies
The robustness studies for artemether and lumefantrine were 
established in the mentioned variance conditions (±2 units change in 
flow rate and detection wavelength). From the results, it was observed 
that the assay values of the test preparation solution were not affected 
and it was in accordance with that of actual. System suitability 
parameters were also found satisfactory concluding robustness of the 
developed method (Table 6).
Solution stability study
The solution stability studies at 100% test concentration of the above 
mentioned drugs in mobile phase were carried out for 24 hrs at 35°C. 
Table 1: System suitability of artemether and lumefantrine
Parameters Artemether Lumefantrine
Number of theoretical plates 3330 5076
Tailing factor 1.36 1.219
Area 2022.473 5681.631
Retention time 2.207 3.733










10 1244.648 20 4245.29
15 1515.123 40 4900.04
20 1875.465 60 5782.059
25 2142.362 80 6951.37
30 2451.356 100 7635.418
Slope, b 60.813 Slope, b 88.310
Intercept, a 629.53 Intercept, a 2370.2
Correlation, r2 0.9982 Correlation, r2 0.9912
Table 5: Results of accuracy of artemether
Recovery level Artemether




50% 10 5.0 14.99 99.98
100% 20 5.0 25.03 100.02
150% 30 5.0 34.97 99.96
Mean recovery*& %RSD 99.98% with %RSD-0.0304%
Recovery level Lumefantrine




50% 20 5.0 24.98 99.97
100% 40 5.0 44.97 99.97
150% 60 5.0 64.94 99.96
Mean recovery*& %RSD 99.96% with %RSD-0.00504%
*Average of three determinations. RSD: Relative standard deviation, 
SD: Standard deviation
Table 3: LOD and LOQ values of artemether and lumefantrine
Sensitivity Parameters Artemether Lumefantrine
LOD (µg/ml) 0.0428 0.142
LOQ (µg/ml) 0.094 0.313
LOD: Limit of detection, LOQ: Limit of quantitation






Peak area Retention 
time
Peak area
Sample 1 2.213 2051.034 3.153 1828.32
Sample 2 2.190 2018.514 3.157 1879.004
Sample 3 2.210 2089.94 3.187 1874.11
Sample 4 2.203 2079.924 3.157 1833.076
Sample 5 2.21 2076.366 3.15 1848.682
Sample 6 2.203 2072.363 3.147 1865.499
%Mean* 2.205 2065 3.159 1855
SD* 0.008 26.0 0.015 21.4
%RSD* 0.378 1.26 0.459 1.15
*Average of six determinations. SD: Standard deviation
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From the above studies, it was found that the mentioned analytes 
were stable in mobile phase for 24 hrs, indicating the solution stability 
(Mobile phase) of analysis in the proposed procedure (Table 7).
Analysis of marketed formulation
Analysis of marketed tablets Combither oral tablets (artemether 20 mg 
and lumefantrine 120 mg) was carried out using the developed sC 
method. The % drug content of artemether and lumefantrine in fixed 
combination dose tablets (combither) were found to be 99.78 and 
99.98%, respectively (Table 8).
CONCLUSION
A new simple, precise, and accurate RP-HPLC method was developed 
and validated for the assay of artemether and lumefantrine in fixed 
combination dose. The proposed method deduced high recoveries 
with good linearity and precision. The validation results cited above 
it were within ICH guidelines, concluding that the proposed RP-HPLC 
method was found to be suitable for the rapid analysis of artemether 
and lumefantrine in fixed combined formulations in quality control 
labs.
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